Sanofi - Aventis Groupe: Press Release: Dupixent® (dupi

Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine Dupixent is the first and only investigational biologic

Related Keywords

Japan , Paris , France General , France , United States , American , Eva Schaefer Jansen , Sandrine Guendoul , Surya Bhatt , Gewinn Nur , Tarik Elgoutni , Sally Bain , Vesna Tosic , Felix Lauscher , Sharon Chen , Nathalie Pham , American Thoracic Society , Regeneron Pharmaceuticals Inc , Twitter , Trial Program , International Conference , Nasdaq , Clinical Research Program , Euronext , Exchange Commission , Regeneron Genetics Center , Pulmonary Research , Dupilumab Development Program , New England Journal , Thoracic Society , England Journal , Recently Published Pulmonary , Clinical Trial Results , Birmingham Division , Critical Care Medicine , Respiratory Questionnaire , Evaluating Respiratory Symptoms , Forward Looking Statements , Private Securities Litigation Reform Act , Statement Regarding Forward Looking , Digital Media , Regeneron Pharmaceuticals , Product Candidates , Sanofi , Eventis , Roupe , Dress , Release , Dupixent , Dupilumab , Gate , Breaking , Hase , Copd , Results , Resented , Psimultaneously , Published , England , Journal , Medicine ,